Permanent Inactivation of HBV Genomes by CRISPR/Cas9-Mediated Non-cleavage Base Editing

Current antiviral therapy fails to cure chronic hepatitis B virus (HBV) infection because of persistent covalently closed circular DNA (cccDNA). CRISPR/Cas9-mediated specific cleavage of cccDNA is a potentially curative strategy for chronic hepatitis B (CHB). However, the CRISPR/Cas system inevitabl...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yu-Chan, Chen, Yu-Hsiang, Kao, Jia-Horng, Ching, Chi, Liu, I-Jung, Wang, Chih-Chiang, Tsai, Cheng-Hsueh, Wu, Fang-Yi, Liu, Chun-Jen, Chen, Pei-Jer, Chen, Ding-Shinn, Yang, Hung-Chih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150432/
https://www.ncbi.nlm.nih.gov/pubmed/32278307
http://dx.doi.org/10.1016/j.omtn.2020.03.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150432/
https://www.ncbi.nlm.nih.gov/pubmed/32278307
http://dx.doi.org/10.1016/j.omtn.2020.03.005

Ejemplares similares